$MMED

iShares Russell 2000 (IWM) rebalanced its portfolio on October 20, with $153.2M in gross activity. It bought $3.6M in MiniMed (MMED), $1.2M in Jackson Financial (JXN), and $0.4M in Axos Financial (AX). It sold $5.5M in Radian Group (RDN), $4.8M in Home BancShares (HOMB), and $4.5M in Essent Group (ESNT).

Medtronic plc (MDT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Medtronic Completes Separation of MiniMed Group, Inc. GALWAY, Ireland, October 15, 2026 – Medtronic plc (Medtronic; NYSE: MDT) today announced the completion of its separation of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). “I’m incredibly proud of what MiniMed and M

MiniMed (MMED) has finalized its Board of Directors post-separation from Medtronic, retaining Kevin E. Lofton as chair and adding Amy Bricker. This marks an early governance milestone for the newly independent company.

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MiniMed Completes Separation from Medtronic NORTHRIDGE, Calif., October 15, 2026 – MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc (“Medtronic”; NYSE: MDT), marking its first day as a fully independent company. “Today marks

MiniMed Group, Inc. (MMED) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. MiniMed Group, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on October 9, 2026 (the “Annual Meeting”), at which stockholders voted on the following four proposals. All matters voted on at the Annu

Rothschild Redburn initiated MiniMed Group (MMED) with a Buy rating and $30 price target, citing improved products and market positioning. The stock trades at $18.80, with projected 10.8% revenue CAGR from 2026-2029. MiniMed reported Q1 revenue of $843M, up 17% YoY, exceeding estimates. Multiple analysts raised price targets post-earnings.

Wall Street analysts issued updates on multiple companies. Biogen (BIIB) was upgraded to Overweight with a $300 target, First Solar (FSLR) to Buy with a $270 target, and Salesforce (CRM) to Buy with a $285 target. Adobe (ADBE) was downgraded to Underweight with a $225 target, and Snowflake (SNOW) to Accumulate with a $515 target. Robinhood (HOOD) was initiated with an Outperform rating and $130 target.

Jefferies initiated coverage on MiniMed Group (NASDAQ:MMED) with a Hold rating and a $22.00 price target, citing improved performance and competitive position. The stock trades at $19.71, with a Fair Value of $22.63 according to InvestingPro. The company reported Q1 revenue of $843 million, up 17% YoY, exceeding expectations. Analysts predict profitability this year, with varied price target updates from other firms.

Medtronic (MDT) announced a final exchange ratio of 4.5939 shares of MiniMed (MMED) for each Medtronic share in its split-off offer. Up to 225.4 million MiniMed shares will be exchanged, with proration if oversubscribed. The offer expires October 9, 2026, unless extended.

MiniMed (MMED) presented clinical trial data showing that users of its Smart MDI system who responded to more alerts had 8.1% more Time in Range and 0.6% lower HbA1c. The six-month study involved 143 people with type 1 diabetes. The Smart MDI system connects a smart insulin pen with a continuous glucose monitor via an app, providing dose calculations and alerts.